

Global antibody production market to reach \$13.28 bn by 2021

26 August 2016 | News | By BioSpectrum Bureau

Global antibody production market to reach \$13.28 bn by 2021



The improved approval rate of therapeutic antibodies by regulatory authorities, patent expiry of blockbuster monoclonal antibodies, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies are driving the overall antibody production market.

The increasing prevalence of infectious diseases and rising demand for protein therapeutics are expected to provide growth opportunities for players operating in this market.

Based on end users, the market is segmented into pharmaceutical and biotechnology companies, research institutes, and diagnostic laboratories.

[See Also: India's medical devices market will hit \\$17.6 bn by 2020](#)

The pharmaceutical and biotechnology companies segment is expected account for the largest share of the antibody production market and is estimated to register the highest CAGR.

The large number of drug development procedures to meet the shortened industry timelines is driving significant investments

by companies towards research and development activities; this is a key market driver for this end-user segment.

The prominent players in the antibody production market include GE Healthcare (US), Thermo Fisher Scientific (US), Sartorius (Germany), Merck KGaA (Germany), Pall (US), Sigma-Aldrich (Germany), Eppendorf AG (Germany), Cellab (Germany), INTEGRA Biosciences (Switzerland), and FiberCell Systems (US).